Cochrane · systematic review · CD002947
Oral herbal therapies for treating osteoarthritis
Cameron, M, Chrubasik, S · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
MusculoskeletalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
56
current version
GRADE rated
29
No studies
18
Included studies
NR
No studies 18 · 32.1%Ungraded 9 · 16.1%Very low 4 · 7.1%Low 7 · 12.5%Moderate 18 · 32.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Boswellia serrata for treating osteoarthritis
Population: patients with treating osteoarthritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain Global pain 0‐3 (higher scores mean worse) | no estimate extracted | 1 study · 30 participants | Low Downgraded: imprecision |
Function Loss of function 0‐3 (higher scores mean worse) | no estimate extracted | 1 study · 30 participants | Low Downgraded: imprecision |
Adverse events Participants (n) reported adverse effects | RR 5 [0.26, 96.13] | 1 study · 30 participants | Low Downgraded: imprecision |
Adverse events Participants (n) withdrew due to adverse effects | no estimate extracted | 1 study · 30 participants | Ungraded |
Adverse events Participants (n) reported serious adverse events | no estimate extracted | NR | No studies |
Radiographic joint changes | no estimate extracted | NR | No studies |
Quality of life | no estimate extracted | NR | No studies |
Boswellia serrata (enriched) 100 mg for treating osteoarthritis
Population: patients with treating osteoarthritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain Global pain VAS 0‐100 (higher scores mean worse) | no estimate extracted | 2 studies · 85 participants | Moderate Downgraded: imprecision |
Function WOMAC‐VAS (Function) | no estimate extracted | 2 studies · 85 participants | Moderate Downgraded: imprecision |
Adverse events Adverse event episodes (n) reported | RR 0.6 [0.39, 0.92] | 1 study · 96 participants | Moderate Downgraded: imprecision |
Adverse events Participants (n) withdrew due to adverse effects | no estimate extracted | 1 study · 96 participants | Ungraded |
Adverse events Participants (n) reported serious adverse events | no estimate extracted | 1 study · 96 participants | Ungraded |
Radiographic joint changes | no estimate extracted | NR | No studies |
Quality of life | no estimate extracted | NR | No studies |
Boswellia serrata (enriched) 250 mg for treating osteoarthritis
Population: patients with treating osteoarthritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain Global pain VAS 0‐100 (higher scores mean worse) | no estimate extracted | 1 study · 47 participants | Moderate Downgraded: imprecision |
Function WOMAC‐VAS (Function) | no estimate extracted | 1 study · 47 participants | Moderate Downgraded: imprecision |
Adverse events Adverse event episodes (n) reported | RR 0.9 [0.62, 1.3] | 1 study · 114 participants | Moderate Downgraded: imprecision |
Adverse events Participants (n) withdrew due to adverse effects | no estimate extracted | 1 study · 114 participants | Ungraded |
Adverse events Participants (n) reported serious adverse events | no estimate extracted | 1 study · 114 participants | Ungraded |
Radiographic joint changes | no estimate extracted | NR | No studies |
Quality of life | no estimate extracted | NR | No studies |
Boswellia serrata (enriched) plus non‐volatile oil for treating osteoarthritis
Population: patients with treating osteoarthritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain Global pain VAS 0‐100 (higher scores mean worse) | no estimate extracted | 2 studies · 97 participants | Moderate Downgraded: imprecision |
Function WOMAC‐VAS (Function) | no estimate extracted | 2 studies · 97 participants | Moderate Downgraded: imprecision |
Adverse events Participants (n) reported adverse events | RR 0.98 [0.14, 6.69] | 2 studies · 97 participants | Moderate Downgraded: imprecision |
Adverse events Participants (n) withdrew due to adverse effects | no estimate extracted | NR | No studies |
Adverse events Participants (n) reported serious adverse events | no estimate extracted | NR | No studies |
Radiographic joint changes | no estimate extracted | NR | No studies |
Quality of life | no estimate extracted | NR | No studies |
Boswellia serrata compared to valdecoxib for treating osteoarthritis
Population: patients with treating osteoarthritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain WOMAC‐VAS (Pain) (higher scores mean worse) Boswellia serrata vs valdecoxib | no estimate extracted | 1 study · 58 participants | Very low |
Function WOMAC‐VAS (Function) Boswellia serrata vs valdecoxib | no estimate extracted | 1 study · 58 participants | Very low |
Adverse events Participants (n) reported adverse events Boswellia serrata vs valdecoxib | RR 2 [0.39, 10.18] | 1 study · 66 participants | Very low |
Adverse events Participants (n) withdrew due to adverse effects Boswellia serrata vs valdecoxib | RR 3 [0.13, 71.07] | 1 study · 66 participants | Very low |
Adverse events Participants (n) reported serious adverse events Boswellia serrata vs valdecoxib | no estimate extracted | 1 study · 66 participants | Ungraded |
Radiographic joint changes Boswellia serrata vs valdecoxib | no estimate extracted | NR | No studies |
Quality of life Boswellia serrata vs valdecoxib | no estimate extracted | NR | No studies |
Persea gratissma + Glycine max (ASU 300 mg) for treating osteoarthritis
Population: patients with osteoarthritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain Global pain VAS 0‐100 (higher scores mean worse) | no estimate extracted | 4 studies · 651 participants | Moderate Downgraded: inconsistency |
Function Multiple tools4 | no estimate extracted | 4 studies · 642 participants | Moderate Downgraded: inconsistency |
Adverse events Participants (n) reported adverse events | RR 1.04 [0.97, 1.12] | 5 studies · 1050 participants | Moderate Downgraded: inconsistency |
Adverse events Participants (n) withdrew due to adverse effects | RR 1.14 [0.73, 1.8] | 1 study · 398 participants | Moderate Downgraded: imprecision, inconsistency |
Adverse events Participants (n) reported serious adverse events | RR 1.22 [0.94, 1.59] | 1 study · 398 participants | Moderate Downgraded: imprecision, inconsistency |
Radiographic joint changes Change in Joint Space Width (JSW) from baseline (higher scores mean worse). | no estimate extracted | 2 studies · 453 participants | Moderate Downgraded: imprecision, inconsistency |
Quality of life | no estimate extracted | NR | No studies |
Persea gratissma + Glycine max (ASU 600 mg) for treating osteoarthritis
Population: patients with osteoarthritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain Global pain VAS 0‐100 (higher scores mean worse) | no estimate extracted | 1 study · 156 participants | Moderate Downgraded: imprecision |
Function Lequesne algofunctional index 0‐24 (higher scores mean worse) | no estimate extracted | 1 study · 156 participants | Moderate Downgraded: imprecision |
Adverse events Participants (n) reported adverse events | RR 1.07 [0.66, 1.74] | 1 study · 174 participants | Moderate Downgraded: imprecision |
Adverse events Participants (n) withdrew due to adverse effects | no estimate extracted | 1 study · 174 participants | Ungraded |
Adverse events Participants (n) reported serious adverse events | no estimate extracted | 1 study · 174 participants | Ungraded |
Radiographic joint changes | no estimate extracted | NR | No studies |
Quality of life | no estimate extracted | NR | No studies |
Persea gratissma + Glycine max (ASU 300 mg) compared to chondroitin sulphate for treating osteoarthritis
Population: patients with osteoarthritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain WOMAC‐VAS (Pain) (higher scores mean worse) Persea gratissma + Glycine max (ASU 300 mg) vs chondroitin sulphate | no estimate extracted | 1 study · 357 participants | Low Downgraded: imprecision |
Function WOMAC‐VAS (Function) (higher scores mean worse) Persea gratissma + Glycine max (ASU 300 mg) vs chondroitin sulphate | no estimate extracted | 1 study · 357 participants | Low Downgraded: imprecision |
Adverse events Participants (n) reported adverse events Persea gratissma + Glycine max (ASU 300 mg) vs chondroitin sulphate | RR 0.86 [0.59, 1.26] | 1 study · 357 participants | Low Downgraded: imprecision |
Adverse events Participants (n) withdrew due to adverse effects Persea gratissma + Glycine max (ASU 300 mg) vs chondroitin sulphate | no estimate extracted | 1 study · 357 participants | Ungraded |
Adverse events Participants (n) reported serious adverse events Persea gratissma + Glycine max (ASU 300 mg) vs chondroitin sulphate | RR 2.92 [0.31, 27.78] | 1 study · 357 participants | Low Downgraded: imprecision |
Radiographic joint changes Persea gratissma + Glycine max (ASU 300 mg) vs chondroitin sulphate | no estimate extracted | NR | No studies |
Quality of life Persea gratissma + Glycine max (ASU 300 mg) vs chondroitin sulphate | no estimate extracted | NR | No studies |